"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive ...

With support from Sanofi and Regeneron, Viz.ai will investigate the use of the Viz COPD module, a care acceleration solution that will leverage electronic health record (EHR) data and artificial ...